OvaGene said this week that it has signed a licensing and collaboration agreement with the Moffitt Cancer Center to develop microRNAs as biomarkers for cancer drug response.
OvaGene said it now has the exclusive rights to to develop and commercialize assays based on miRNAs validated by Moffitt researcher Johnathan Lancaster. The company said it would initially focus on a test that can predict an ovarian cancer patient's response to treatment, and expects to have a product ready for market in 18 to 24 months.
The firm said it would create additional assays to predict drug response to other gynecologic cancers in the future.